Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hernan Carol

Showing results (1-10 of 64) with videos related to

Pageof 7
Sort By:
Human Vaccines & Immunotherapeutics|June 21, 2016
TriKEs and BiKEs join CARs on the cancer immunotherapy highwaySzun Szun Tay, Hernan Carol, Maté Biro
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 22, 2013
The anti-CD19 antibody-drug conjugate SAR3419 prevents hematolymphoid relapse postinduction therapy in preclinical models of pediatric acute lymphoblastic leukemiaHernan Carol, Barbara Szymanska, Kathryn Evans, et al.
British Journal of Cancer|June 16, 2020
Examining treatment responses of diagnostic marrow in murine xenografts to predict relapse in children with acute lymphoblastic leukaemiaAbdulmohsen M Alruwetei, Katerina Bendak, Babasaheb D Yadav, et al.
Pediatric Blood & Cancer|September 10, 2014
Efficacy of CPX-351, (cytarabine:daunorubicin) liposome injection, against acute lymphoblastic leukemia (ALL) xenograft models of the Pediatric Preclinical Testing ProgramHernan Carol, Mannie M Y Fan, Troy O Harasym, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 26, 2017
Bioluminescence Imaging Enhances Analysis of Drug Responses in a Patient-Derived Xenograft Model of Pediatric ALLLuke Jones, Jennifer Richmond, Kathryn Evans, et al.
Plos One|April 6, 2012
Pharmacokinetic modeling of an induction regimen for in vivo combined testing of novel drugs against pediatric acute lymphoblastic leukemia xenograftsBarbara Szymanska, Urszula Wilczynska-Kalak, Min H Kang, et al.
Pediatric Blood & Cancer|December 19, 2007
Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing programRichard Lock, Hernan Carol, Peter J Houghton, et al.
Pediatric Blood & Cancer|April 11, 2007
Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing programPeter J Houghton, Christopher L Morton, E Anders Kolb, et al.
Pediatric Blood & Cancer|June 26, 2009
Initial testing (stage 1) of the kinesin spindle protein inhibitor ispinesib by the pediatric preclinical testing programHernan Carol, Richard Lock, Peter J Houghton, et al.
Pediatric Blood & Cancer|February 9, 2008
Stage 1 testing and pharmacodynamic evaluation of the HSP90 inhibitor alvespimycin (17-DMAG, KOS-1022) by the pediatric preclinical testing programMalcolm A Smith, Christopher L Morton, Doris A Phelps, et al.
Pageof 7

Showing results (1-10 of 64) with videos related to

Sort By:
Pageof 7
Human Vaccines & Immunotherapeutics|June 21, 2016
TriKEs and BiKEs join CARs on the cancer immunotherapy highwaySzun Szun Tay, Hernan Carol, Maté Biro
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 22, 2013
The anti-CD19 antibody-drug conjugate SAR3419 prevents hematolymphoid relapse postinduction therapy in preclinical models of pediatric acute lymphoblastic leukemiaHernan Carol, Barbara Szymanska, Kathryn Evans, et al.
British Journal of Cancer|June 16, 2020
Examining treatment responses of diagnostic marrow in murine xenografts to predict relapse in children with acute lymphoblastic leukaemiaAbdulmohsen M Alruwetei, Katerina Bendak, Babasaheb D Yadav, et al.
Pediatric Blood & Cancer|September 10, 2014
Efficacy of CPX-351, (cytarabine:daunorubicin) liposome injection, against acute lymphoblastic leukemia (ALL) xenograft models of the Pediatric Preclinical Testing ProgramHernan Carol, Mannie M Y Fan, Troy O Harasym, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 26, 2017
Bioluminescence Imaging Enhances Analysis of Drug Responses in a Patient-Derived Xenograft Model of Pediatric ALLLuke Jones, Jennifer Richmond, Kathryn Evans, et al.
Plos One|April 6, 2012
Pharmacokinetic modeling of an induction regimen for in vivo combined testing of novel drugs against pediatric acute lymphoblastic leukemia xenograftsBarbara Szymanska, Urszula Wilczynska-Kalak, Min H Kang, et al.
Pediatric Blood & Cancer|December 19, 2007
Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing programRichard Lock, Hernan Carol, Peter J Houghton, et al.
Pediatric Blood & Cancer|April 11, 2007
Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing programPeter J Houghton, Christopher L Morton, E Anders Kolb, et al.
Pediatric Blood & Cancer|June 26, 2009
Initial testing (stage 1) of the kinesin spindle protein inhibitor ispinesib by the pediatric preclinical testing programHernan Carol, Richard Lock, Peter J Houghton, et al.
Pediatric Blood & Cancer|February 9, 2008
Stage 1 testing and pharmacodynamic evaluation of the HSP90 inhibitor alvespimycin (17-DMAG, KOS-1022) by the pediatric preclinical testing programMalcolm A Smith, Christopher L Morton, Doris A Phelps, et al.
Pageof 7